Published Time: 2026-03-06T08:00:00-05:00
The Phase 2 RECONNOITER trial evaluated AISA-021 (cilnidipine) in patients with systemic sclerosis-associated Raynaud's phenomenon.
The company announced encouraging results from this clinical trial.
AISA-021 is a cilnidipine-based investigational therapy.
Systemic sclerosis-associated Raynaud's phenomenon is a vascular complication characterized by reduced blood flow to extremities.
Based on these positive Phase 2 results, Aisa Pharma plans to advance the development program.
This press release was distributed by PR Newswire. Further details on the trial design and specific efficacy endpoints are anticipated.
